E3A Healthcare proudly introduces Nora, our groundbreaking neuromodulation-based therapeutic device specifically developed for the treatment of endometriosis—a chronic condition impacting approximately 15% (300M) of women worldwide, characterized by severe chronic pain, infertility, and significant healthcare costs. Current treatments lack effectiveness, often relying heavily on invasive procedures or long-term medication use without fully addressing disease progression.

Nora represents a significant advancement, providing a first-in-class, non-invasive, drug-free approach that effectively manages both pain relief and disease progression. Utilizing proprietary vagus nerve stimulation technology, Nora precisely targets neurological pathways associated with pain and inflammation, delivering effective symptom relief while potentially slowing disease progression. Nora's innovative approach holds tremendous potential for improving patient quality of life, reducing healthcare expenses, and providing substantial cost savings compared to conventional treatments, particularly within major healthcare markets such as the US and EU.

Phase I Animal Study Successful & Published

Our neuromodulation therapy system has shown significant efficacy in both pain relief and lesion suppression in preclinical models of endometriosis.The underlying mechanisms—focusing on protein receptors and neural pathways involved in endometrial fibrosis—have been rigorously studied and published in top peer-reviewed journals include Nature Scientific Reports, and the Journal of Reproductive Biology.

Phase II Human Pilot Study Completed

Building on the success of our animal studies, we have completed a human pilot study that further validated the efficacy of our technology in

treating endometriosis and adenomyosis, demonstrating strong potential for clinical application.